E-LIB Suche - Ergebnisse für: Spoorendonk, J. A.

1

A cost-consequence model of using the 21-gene assay to iden..:

Simons, Martijn J. H. G. ; Machielsen, Peter M. ; Spoorendonk, Jelle A....
Journal of Medical Economics. 27 (2024) 1 - p. 445-454 , 2024

Link: https://doi.org/10.1080/..

2

A cost-consequence model of using the 21-gene assay to iden..:

Martijn J.H.G. Simons ; Peter M. Machielsen ; Jelle A. Spoorendonk...
doi:10.6084/m9.figshare.25334767.v1. , 2024

Link: https://doi.org/10.6084/..

3

A cost-consequence model of using the 21-gene assay to iden..:

Martijn J.H.G. Simons ; Peter M. Machielsen ; Jelle A. Spoorendonk...
doi:10.6084/m9.figshare.25334767.v1. , 2024

Link: https://doi.org/10.6084/..

4

The feasibility of a 12-week progressive strength training ..:

Kierkegaard-Brøchner, S. ; Kemp, J. ; Lund, B....
Journal of Science and Medicine in Sport. 26 (2023) - p. S123-S124 , 2023

Link: https://doi.org/10.1016/..

5

coin-or/Osi: Release releases/0.108.8:

John Forrest ; Stefan Vigerske ; Lou Hafer...
https://github.com/coin-or/Osi/tree/releases/0.108.8. , 2023

Link: https://zenodo.org/recor..

6

coin-or/python-mip: 1.15.0:

Haroldo Gambini Santos ; Túlio Toffolo ; Sebastian Heger...
https://github.com/coin-or/python-mip/tree/1.15.0. , 2023

Link: https://zenodo.org/recor..

7

25 Strength, function and overall health before and after s..:

Bent Lund ; Marie Bagger Bohn ; Kasper Spoorendonk..
https://doaj.org/toc/2055-7647. , 2023

Link: https://doi.org/10.1136/..

8

CO49 Clinical Efficacy and Safety of Therapeutic Interventi..:

Jain, P ; Badgujar, L ; Spoorendonk, JA.
Value in Health. 25 (2022) 7 - p. S312-S313 , 2022

Link: https://doi.org/10.1016/..

9

POSC64 Healthcare Costs and Resource Utilization in 1L Main..:

Heldt, D ; Snedecor, SJ ; Kalilani, L...
Value in Health. 25 (2022) 1 - p. S98-S99 , 2022

Link: https://doi.org/10.1016/..

10

POSB276 Network Meta-Analyses of Nivolumab Plus Fluoropyrim..:

Grevinga, M ; Bouwmeester, W ; Spoorendonk, JA...
Value in Health. 25 (2022) 1 - p. S180-S181 , 2022

Link: https://doi.org/10.1016/..

11

MSR126 Economic and Humanistic Burden in Patients With Obst..:

Spoorendonk, JA ; Şahbaz Gülser, S ; Arca`, E...
Value in Health. 25 (2022) 12 - p. S374 , 2022

Link: https://doi.org/10.1016/..

12

POSB97 Cost-Consequence Model of Using Gene Expression Test..:

de Jongh, FE ; Efe, R ; Herrmann, K..
Value in Health. 25 (2022) 1 - p. S79-S80 , 2022

Link: https://doi.org/10.1016/..

13

POSB11 Correlation and Prognostic Value of Surrogate Endpoi..:

Yucel, E ; Malcolm, B ; Diakite, I...
Value in Health. 25 (2022) 1 - p. S26-S27 , 2022

Link: https://doi.org/10.1016/..

14

MSR97 Systematic Literature Review of the Efficacy and Safe..:

Spoorendonk, JA ; Şahbaz Gülser, S ; Arca`, E...
Value in Health. 25 (2022) 12 - p. S368 , 2022

Link: https://doi.org/10.1016/..

15

EE529 Modeling Studies of Human Papilloma Virus (HPV) Vacci..:

Wang, W ; Jain, P ; Santpurkar, N...
Value in Health. 25 (2022) 12 - p. S160 , 2022

Link: https://doi.org/10.1016/..